Drug intelligence / Profile preview

Augment-Tasmania influenza vaccine

Development stage: Phase 1
Lead developer: Sanofi Pasteur
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Augment-Tasmania influenza vaccine is an influenza vaccine formulation developed by Sanofi Pasteur. It is designed to provide immunity against influenza by including WHO-recommended virus strains along with an additional H3 antigen. The vaccine is administered intramuscularly and is currently being evaluated in a Phase I clinical trial to assess its safety and immunogenicity in healthy adult participants.

Targets

HA (Hemagglutinin)

Beyond the preview

Go deeper on Augment-Tasmania influenza vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Augment-Tasmania influenza vaccine.

Explore the full profile